Editorial: Utilizing real-world evidence for better endocrine health management

and insulin or glinide use as key risk factors for hypoglycemia, with distinct temporal patterns， providing a basis for targeted inpatient monitoring and intervention strategies. However, this will require addressing practical challenges such as acceptance by guideline developers, quality standards, and data harmonization. Further optimization of RWD/RWE is required, including establishing unified standards for endocrine RWD data collection, advancing statistical methods for confounding adjustment and causal inference, enhancing multicenter data sharing, developing affordable RWD-based tools for resource-limited settings, and integrating highquality RWE into clinical guidelines via cross-sector collaboration (Figure 1). Together, these studies underscore the transformative potential of RWD/RWE in shaping evidence-based clinical decision-making and advancing the systemic management of endocrine diseases.